scholarly journals Insights into Brain Signal Transduction can Provide Potential Molecular Targets to Approach and Manage Alzheimer’s Disease

2020 ◽  
Vol 4 (2) ◽  
pp. 1-22
Author(s):  
Vincenza Rita Lo Vasco ◽  
2018 ◽  
Vol 15 (4) ◽  
pp. 355-362 ◽  
Author(s):  
Vincenza Rita Lo Vasco

Background: During aging and in age-associated disorders, such as Alzheimer's Disease (AD), learning abilities decline. Probably, disturbances in signal transduction in brain cells underlie the cognitive decline. The phosphorylation/dephosphorylation imbalance occurring in degenerating neurons was recently related to abnormal activity of one or more signal transduction pathways. AD is known to be associated with altered neuronal Ca<sup>2+</sup> homeostasis, as Ca<sup>2+</sup> accumulates in affected neurons leading to functional impairment. It is becoming more and more evident the involvement of signal transduction pathways acting upon Ca<sup>2+</sup> metabolism and phosphorylation regulation of proteins. A growing interest raised around the role of signal transduction systems in a number of human diseases including neurodegenerative diseases, with special regard to the systems related to the phosphoinositide (PI) pathway and AD. The PI signal transduction pathway plays a crucial role, being involved in a variety of cell functions, such as hormone secretion, neurotransmitter signal transduction, cell growth, membrane trafficking, ion channel activity, cytoskeleton regulation, cell cycle control, apoptosis, cell and tissue polarity, and contributes to regulate the Ca<sup>2+</sup> levels in the nervous tissue. Conclusion: A number of observations indicated that PI-specific phospholipase C (PLC) enzymes might be involved in the alteration of neurotransmission. To understand the role and the timing of action of the signalling pathways recruited during the brain morphology changes during the AD progression might help to elucidate the aetiopathogenesis of the disease, paving the way to prognosis refinement and/or novel molecular therapeutic strategies.


Author(s):  
Tanay Dalvi ◽  
Bhaskar Dewangan ◽  
Rudradip Das ◽  
Jyoti Rani ◽  
Suchita Dattatray Shinde ◽  
...  

: The most common reason behind dementia is Alzheimer’s disease (AD) and it is predicted to be the third lifethreatening disease apart from stroke and cancer for the geriatric population. Till now only four drugs are available in the market for symptomatic relief. The complex nature of disease pathophysiology and lack of concrete evidences of molecular targets are the major hurdles for developing new drug to treat AD. The the rate of attrition of many advanced drugs at clinical stages, makes the de novo discovery process very expensive. Alternatively, Drug Repurposing (DR) is an attractive tool to develop drugs for AD in a less tedious and economic way. Therefore, continuous efforts are being made to develop a new drug for AD by repursing old drugs through screening and data mining. For example, the survey in the drug pipeline for Phase III clinical trials (till February 2019) which has 27 candidates, and around half of the number are drugs which have already been approved for other indications. Although in the past the drug repurposing process for AD has been reviewed in the context of disease areas, molecular targets, there is no systematic review of repurposed drugs for AD from the recent drug development pipeline (2019-2020). In this manuscript, we are reviewing the clinical candidates for AD with emphasis on their development history including molecular targets and the relevance of the target for AD.


1995 ◽  
Vol 149-150 (1) ◽  
pp. 287-292 ◽  
Author(s):  
Christopher J. Fowler ◽  
Richard F. Cowburn ◽  
Anita Garlind ◽  
Bengt Winblad ◽  
Cora O'Neill

Neurosignals ◽  
2002 ◽  
Vol 11 (5) ◽  
pp. 235-235 ◽  
Author(s):  
Mark A. Smith ◽  
Xiongwei Zhu ◽  
George Perry

1999 ◽  
Vol 20 (2-3) ◽  
pp. 93-109 ◽  
Author(s):  
René Etcheberrigaray ◽  
Seetha Bhagavan

2020 ◽  
Vol 58 (1) ◽  
pp. 281-303
Author(s):  
Md. Sahab Uddin ◽  
Abdullah Al Mamun ◽  
Md. Tanvir Kabir ◽  
Ghulam Md Ashraf ◽  
May N. Bin-Jumah ◽  
...  

The Analyst ◽  
2020 ◽  
Vol 145 (8) ◽  
pp. 2925-2936
Author(s):  
Son T. Le ◽  
Michelle A. Morris ◽  
Antonio Cardone ◽  
Nicholas B. Guros ◽  
Jeffery B. Klauda ◽  
...  

Commercially sourced silicon field-effect transistors enable sensitive measurements of small therapeutic molecules that regulate enzymes implicated in Alzheimer's disease.


2019 ◽  
Vol 56 (10) ◽  
pp. 7032-7044 ◽  
Author(s):  
Geir Bjørklund ◽  
Jan Aaseth ◽  
Maryam Dadar ◽  
Salvatore Chirumbolo

Sign in / Sign up

Export Citation Format

Share Document